Systemic Lupus Erythematosus (SLE) Treatments

Find Systemic Lupus Erythematosus (SLE) Treatments

Living with Systemic Lupus Erythematosus (SLE), or lupus, means navigating an autoimmune condition where the body’s immune system mistakenly attacks healthy tissues. This can result in widespread inflammation, causing fatigue, joint pain, rashes, and damage to vital organs like the kidneys, heart, and brain. The unpredictable nature of lupus, marked by periods of flares and remission, can significantly impact a person’s energy, mobility, and overall quality of life.

Treatment is crucial to calm the overactive immune system, control inflammation, prevent flares, and minimize long-term organ damage. Because lupus symptoms can range from mild joint aches to severe kidney failure, medication choices are highly individualized. A person with primarily skin and joint involvement will have a very different treatment plan than someone experiencing lupus nephritis (kidney inflammation) or central nervous system involvement (Arthritis Foundation, 2023).

Overview of treatment options for Systemic Lupus Erythematosus

The main goals of treating SLE are achieving and maintaining disease remission, managing acute flares, and preventing permanent organ damage. Treatment is typically tailored to address both the underlying immune dysregulation and the specific symptoms being experienced.

For mild disease, the focus is often on antimalarials and non-steroidal anti-inflammatory drugs (NSAIDs) to manage pain and prevent flares. For moderate to severe disease, which involves significant organ involvement, stronger medications are needed to suppress the immune system aggressively. These include corticosteroids, immunosuppressants, and newer biologic therapies. While medication is central, essential supportive care includes sun protection, stress reduction, and avoiding certain triggers.

Medications used for Systemic Lupus Erythematosus

The treatment regimen for lupus typically relies on several key drug classes:

  1. Antimalarials: These are often the first-line and cornerstone therapy for lupus, regardless of severity. Hydroxychloroquine is the most common example. They help prevent flares, treat fatigue, and manage skin and joint symptoms. These drugs work slowly, often taking several weeks or months to show full benefit.
  2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs): Medications like ibuprofen or naproxen are used to manage mild joint pain, muscle aches, and fever associated with minor flares.
  3. Corticosteroids: Drugs such as prednisone are fast-acting, powerful anti-inflammatory agents used to quickly control severe flares or treat life-threatening complications like lupus nephritis.
  4. Immunosuppressants/Cytotoxics: These are prescribed for severe or active disease, especially when major organs are affected. Examples include mycophenolate mofetil and azathioprine. These drugs are used to control inflammation and spare the patient from long-term, high-dose steroid use.
  5. Biologics: These newer therapies target specific components of the immune system. Belimumab is a biologic approved to reduce disease activity in adults with active, autoantibody-positive SLE. Studies show biologics can significantly reduce disease activity, especially in patients who haven’t responded well to standard treatment (Centers for Disease Control and Prevention, 2022).

How these medications work

The major drug classes work by interrupting the immune cascade that fuels lupus:

  • Antimalarials (e.g., hydroxychloroquine) stabilize the immune response by accumulating in immune cells and interfering with cytokine signaling, preventing self-damage.
  • Corticosteroids act quickly and broadly to reduce the production of inflammatory chemicals, effectively stopping an acute immune flare.
  • Immunosuppressants slow the growth of lymphocytes, the cells responsible for creating tissue-attacking autoantibodies, thus lowering overall autoimmune disease activity.
  • Biologics target specific proteins or B cells involved in lupus; for instance, belimumab limits autoantibody production by inhibiting a B cell survival protein.

Side effects and safety considerations

Lupus medications, especially immune suppressants, need careful monitoring.

  • Antimalarials require regular eye exams due to rare retinal risk.
  • Corticosteroids cause significant long-term side effects (weight gain, osteoporosis, high blood pressure, infection risk) and must be slowly tapered.
  • Immunosuppressants lower white blood cells, increasing infection risk, and require regular labs for liver/kidney function.
  • Biologics slightly increase infection risk and may cause infusion reactions.

Patients should seek immediate care for signs of severe allergic reaction, high fever, or unexpected bleeding. Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. Arthritis Foundation. https://www.arthritis.org
  2. Centers for Disease Control and Prevention. https://www.cdc.gov
  3. Mayo Clinic. https://www.mayoclinic.org
  4. National Institutes of Health. https://www.nih.gov

Medications for Systemic Lupus Erythematosus (SLE)

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Systemic Lupus Erythematosus (SLE).

Found 12 Approved Drugs for Systemic Lupus Erythematosus (SLE)

MethylPREDNISolone

Brand Names
Solu-Medrol MethylPREDNISolone, Solu-Medrol, Medrol

MethylPREDNISolone

Brand Names
Solu-Medrol MethylPREDNISolone, Solu-Medrol, Medrol
Methylprednisolone tablets are indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis EpicondylitisAcute gouty arthritis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Nervous System Acute exacerbations of multiple sclerosis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

Hydroxychloroquine

Brand Names
Plaquenil, Sovuna

Hydroxychloroquine

Brand Names
Plaquenil, Sovuna
Hydroxychloroquine sulfate tablets is an antimalarial and antirheumatic indicated for the: Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax in adult and pediatric patients.

Benlysta

Generic Name
Belimumab

Benlysta

Generic Name
Belimumab
BENLYSTA (belimumab) is indicated for the treatment of: patients 5 years of age and older with active systemic lupus erythematosus (SLE) who are receiving standard therapy, and, patients 5 years of age and older with active lupus nephritis who are receiving standard therapy. Limitations of Use The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system (CNS) lupus. Use of BENLYSTA is not recommended in this situation. BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of:, patients 5 years of age and older with active systemic lupus erythematosus (SLE) who are receiving standard therapy; ( 1 ), patients 5 years of age and older with active lupus nephritis who are receiving standard therapy. ( 1 ) Limitations of Use: The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system lupus. Use of BENLYSTA is not recommended in this situation. ( 1 )

Lupkynis

Generic Name
Voclosporin

Lupkynis

Generic Name
Voclosporin
LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN). Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation. LUPKYNIS is a calcineurin-inhibitor immunosuppressant indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN). ( 1, 14 ) Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation.

Gazyva

Generic Name
Obinutuzumab

Gazyva

Generic Name
Obinutuzumab
GAZYVA (obinutuzumab) is a CD20-directed cytolytic antibody indicated: in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia. ( 1, 14 ) in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. ( 1, 14 ) in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma. ( 1, 14 )
Showing 1-5 of 12
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances